Clinical Trial Update: Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the maximum tolerated dose of liposomal doxorubicin in combination with seliciclib for metastatic triple-negative breast cancer has b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• liposomal doxorubicin (doxorubicin liposomal)
• seliciclib (seliciclib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Breast Cancer | Phase 1 | Status: WITHDRAWN